At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
Garadacimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Garadacimab in Subjects With Idiopathic Pulmonary Fibrosis
In Brief
A Phase 2 clinical trial evaluating Garadacimab and Placebo for Idiopathic Pulmonary Fibrosis. Completed, enrolled 81 participants across 47 sites in 11 countries.
Detailed Summary
This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic pulmonary fibrosis (IPF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesAustralia, Austria, Belgium, Canada, Denmark, Germany, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartFeb 2022
Primary CompletionJan 2024
TodayJul 2026
First PostedNov 23, 2021
Enrollment StartFeb 3, 2022
Primary CompletionJan 2, 2024
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.6 years ago
Interventions
Garadacimabdrug
Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.
Placebodrug
Participants received a matching placebo IV loading dose, followed by 3 SC doses.